Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03910569 · ClinicalTrials.gov registry record
The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study
A clinical trial of Takotsubo Cardiomyopathy, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT03910569 is a study of Takotsubo Cardiomyopathy that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 1,000 participants, above the 197-participant average among 3 other Takotsubo Cardiomyopathy trials with a reported enrollment target (408% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03910569, a study of Takotsubo Cardiomyopathy, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.
Conditions Studied
Study Locations (1)
California
- Cedars Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2029-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03910569
The ClinicalTrials.gov registry entry for NCT03910569 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 197-participant average among 3 other Takotsubo Cardiomyopathy trials with a reported enrollment target (408% higher). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Takotsubo Cardiomyopathy appearing as the primary indexed condition, and to 0 interventions.
NCT03910569 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03910569 about?
NCT03910569 is a clinical study titled "The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study". The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria...
What is the current status of trial NCT03910569?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2019-02-01. Estimated completion is 2029-02.
What conditions does trial NCT03910569 study?
This clinical trial studies the following conditions: Takotsubo Cardiomyopathy.
Who is sponsoring clinical trial NCT03910569?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03910569 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Takotsubo Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.